Gilead Sciences Inc. and Terray Therapeutics Inc. have entered into a strategic collaboration to discover and develop novel small-molecule therapies across multiple targets.
SK Biopharmaceuticals Co. Ltd. and Proen Therapeutics Co. Ltd. joined hands in a research collaboration to advance up to two preclinical small protein-based radiopharmaceuticals by 2027 – the year SK Biopharmaceuticals aims to “become a leading radiopharma player” worldwide.
SK Biopharmaceuticals Co. Ltd. has signed a research collaboration agreement with Proen Therapeutics Inc. to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies.
